Πλοήγηση ανά Συγγραφέα "Manoussakis, M. N."
-
Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis
Zachou, K.; Gampeta, S.; Gatselis, N. K.; Oikonomou, K.; Goulis, J.; Manoussakis, M. N.; Renaudineau, Y.; Bogdanos, D. P.; Dalekos, G. N. (2015)Background & AimsAntibodies (Abs) to soluble liver antigen/liver pancreas (anti-SLA/LP) are considered markers of worse prognosis and outcome in patients with autoimmune hepatitis (AIH) although this assumption has recently ... -
HLA DR-DQ haplotypes and genotypes in patients with systemic lupus erythematosus with co-existing Sjogren's syndrome, systemic lupus erythematosus without Sjogren's syndrome and primary Sjogren's syndrome: clinical and laboratory associations
Georgopoulou, C.; Zintzaras, E.; Papadimitropouls, M.; Spyropoulou, M.; Stavropoulou, A.; Moutsopoulos, H. M.; Manoussakis, M. N. (2005) -
Immunogenetic associations in patients with primary Sjogren's syndrome (pSS), SLE with co-existing Sjogren's syndrome (SLE-SS) and SLE without Sjogren's syndrome (SLE-noSS)
Georgopoulou, C.; Zintzaras, E.; Papadimitropoulos, M.; Spyropoulou, M.; Stavropoulou, A.; Skopouli, F. N.; Moutsopoulos, H. M.; Manoussakis, M. N. (2004) -
Impaired degradation and aberrant phagocytosis of necrotic cell debris in the peripheral blood of patients with primary Sjogren's syndrome
Fragoulis, G. E.; Vakrakou, A. G.; Papadopoulou, A.; Germenis, A.; Kanavakis, E.; Moutsopoulos, H. M.; Manoussakis, M. N. (2015)Aberrant removal of necrotic debris is considered a feature with inflammatory consequences in SLE. Herein, primary Sjogren's syndrome (SS) patients were investigated for the first time for the capacity of their sera to ... -
Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: A 20-month open treatment
Cherouvim, E. P.; Zintzaras, E.; Boki, K. A.; Moutsopoulos, H. M.; Manoussakis, M. N. (2004)Background: Infliximab at the dose of 5 mg/kg per infusion has been shown effective for the treatment of active spondyloarthropathies. It is not clear if the 5 mg/kg is required in most patients. Objective: To evaluate the ... -
Sjogren's syndrome associated with systemic lupus erythematosus - Clinical and laboratory profiles and comparison with primary Sjogren's syndrome
Manoussakis, M. N.; Georgopoulou, C.; Zintzaras, E.; Spyropoulou, M.; Stavropoulou, A.; Skopouli, F. N.; Moutsopoulos, H. M. (2004)Objective. To address the clinical, serologic, pathologic, and immunogenetic features of sicca syndrome that occurs in systemic lupus erythematosus (SLE), as well as its similarities to, and differences from, sicca syndrome ...